Legend Biotech To Present At The 44Th Annual J.P. Morgan Healthcare Conference

(MENAFN- GlobeNewsWire - Nasdaq) SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will present the latest company updates at the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14^th, 2026, at 9:00 a.m. PT.

The live webcast will be available to investors and other interested parties by accessing the Investor Relations

ABOUT LEGEND BIOTECH

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at and follow us on X (formerly Twitter) and LinkedIn.

INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
...

PRESS CONTACT:
Alexandra Ventura
Tel: (732) 850-5598
...

MENAFN17122025004107003653ID1110492472